Skip to main content
Figure 2 | BMC Musculoskeletal Disorders

Figure 2

From: Effective osteoporosis treatment with teriparatide is associated with enhanced quality of life in postmenopausal women with osteoporosis: the European Forsteo Observational Study

Figure 2

EQ-VAS changes from baseline. Adjusted mean (SE) change in EQ-VAS from baseline during and after teriparatide treatment in the total study cohort and according to recent prior fracture (within last 12 months) and incident fracture status. Data presented is from the MMRM analysis (adjusted for age, duration of prior bisphosphonate treatment and a diagnosis of rheumatoid arthritis at baseline). All p < 0.05 for within-group change from baseline (except for no recent prior/incident fracture at 6, 24 and 36 months). Significant pairwise comparisons between subgroups at 18 and 36 months are shown in the figure but the same pairwise comparisons were significant (p < 0.05) at 6, 12 and 24 months. *p < 0.05 for recent prior/incident fracture (group A) versus recent prior/no incident fracture (group B); †p < 0.05 for recent prior/incident fracture (group A) versus no recent prior/no incident fracture (group D); ‡ p < 0.001 for recent prior/no incident fracture (group B) versus no recent prior/incident fracture (group C); X p < 0.001 for no recent prior/incident fracture (group C) versus no recent prior/no incident fracture (group D). Note: variability (standard error bars) only added to the graph at two time points (18 and 36 months) for clarity.

Back to article page